Literature DB >> 15798532

[Retroperitoneal fibrosis].

H Kaaroud1, El Jeri, S Béji, F Ben Moussa, F Ben Hamida, S Turki, H Hedri, T Ben Abdallah, A Khedher, M Chebil, H Ben Maïz.   

Abstract

OBJECTIVE: We studied the clinical, therapeutic and progressive characteristics of retroperitoneal fibrosis.
METHODS: We analysed the observations of retroperitoneal fibrosis diagnosed between 1980 and 2002 in our hospital, from the summaries of 15 patients exhibiting retroperitoneal fibrosis (RPF). Therapeutical supervision was based on biology and radiology.
RESULTS: There were 11 men and 4 women with a mean age of 44.5 years ranging from 28-64 years. Pain was predominantly lumbar or abdominal in all patients. An inflammatory syndrome was observed in all patients and renal failure in 11. Radiological examinations revealed single or bilateral in 14 cases and the fibrosis plaque in 13 cases. Treatment consisted in corticosteroids alone in 9 patients, surgery alone in 3 cases and surgery with corticosteroids in 3 patients. Ten relapses (range: 1-5) occurred in 4 patients when corticosteroids were stopped. After a mean follow-up of 36 months (range:18 days-11 years), one death was observed, 12 patients had normal renal function and 2 patients had persistent moderate renal failure.
CONCLUSION: This study confirms the rarity of retroperitoneal fibrosis, the difficulty in its diagnosis, the frequency of pain, inflammatory syndrome and renal failure. Corticosteroids are efficient and regular follow-up is required.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15798532     DOI: 10.1016/s0755-4982(05)88250-8

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  1 in total

1.  Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy.

Authors:  Floor E van der Bilt; Tadek R Hendriksz; Wilbert A G van der Meijden; Lisette G Brilman; Eric F H van Bommel
Journal:  Clin Kidney J       Date:  2016-01-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.